Pantoprazole may improve beta cell function and diabetes mellitus

Area of Science:

• Endocrinology
• Metabolic Diseases
• Pharmacology

Background:

• Proton pump inhibitors (PPIs) suppress gastric acid, leading to hypergastrinemia.
• Elevated gastrin levels can stimulate pancreatic beta cells, mimicking incretin effects.
• Previous studies suggest PPIs may reduce glycosylated hemoglobin (HbA1c).

Purpose of the Study:

• To investigate the impact of pantoprazole on beta cell function in diabetic and non-diabetic individuals.
• To assess changes in glycemic control and beta cell markers during pantoprazole treatment.

Main Methods:

• A 12-week study involving 79 male patients (38 non-diabetic, 41 type-2 diabetic on metformin).
• Pantoprazole 40 mg/day was administered.
• Measurements included fasting plasma glucose (FPG), HbA1c, fasting insulin, HOMA-B (beta cell function), proinsulin, and c-peptide.

Main Results:

• In non-diabetic patients, pantoprazole decreased FPG and increased c-peptide and HOMA-B.
• In type 2 diabetic patients, pantoprazole reduced FPG, HbA1c, and weight, while increasing HOMA-B, c-peptide, and proinsulin.
• Beta cell function correlated positively with c-peptide and insulin, and inversely with FBG and HbA1c.

Conclusions:

• Pantoprazole administration appears to enhance beta cell function and improve glycemic control (HbA1c, FPG).
• The study indicates pantoprazole may positively influence beta cell function markers like HOMA-B, c-peptide, and proinsulin.
• Given the role of beta cell dysfunction in type 2 diabetes, PPIs warrant consideration as a potential adjunctive therapy.